Lack of tocilizumab effect on mortality in COVID19 patients
Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2020-10, Vol.10 (1), p.17100-17100, Article 17100 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17100 |
|---|---|
| container_issue | 1 |
| container_start_page | 17100 |
| container_title | Scientific reports |
| container_volume | 10 |
| creator | Holt, Gregory E. Batra, Mayank Murthi, Mukunthan Kambali, Shweta Santos, Kayo Bastidas, Maria Virginia Perez Asif, Huda Haddadi, Sara Arias, Sixto Mirsaeidi, Mehdi |
| description | Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations. |
| doi_str_mv | 10.1038/s41598-020-74328-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7555891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2451135462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-10d42f7d0a6997f74349aa8a70e918657500a219d08b5695b85557a316064e143</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobsz9AS-kl95U89kmCILMr8FgN-ptSNt0ZrbNTFrZ_PVGO8e8MTcncN7znMMDwCmCFwgSfukpYoLHEMM4pQTzeH0AhhhSFmOC8eHefwDG3i9heAwLisQxGBACGWKEDsHVTOVvkS2j1uamMp9drbJIl6XO28g2UW1dqyrTbiLTRJP5y_QWiWilWqOb1p-Ao1JVXo-3dQSe7--eJo_xbP4wndzM4pzSpI0RLCgu0wKqRIi0DNdSoRRXKdQC8YSlDEKFkSggz1giWMYZY6kiKIEJ1YiSEbjuuasuq3WRh91OVXLlTK3cRlpl5N9OY17lwn7INIC4QAFwvgU4-95p38ra-FxXlWq07bzElCFEGE1wiOI-mjvrvdPlbg2C8lu87MXLIF7-iJfrMHS2f-Bu5FdzCJA-4EOrWWgnl7ZzTZD2H_YLSpiMxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451135462</pqid></control><display><type>article</type><title>Lack of tocilizumab effect on mortality in COVID19 patients</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>EZB Electronic Journals Library</source><creator>Holt, Gregory E. ; Batra, Mayank ; Murthi, Mukunthan ; Kambali, Shweta ; Santos, Kayo ; Bastidas, Maria Virginia Perez ; Asif, Huda ; Haddadi, Sara ; Arias, Sixto ; Mirsaeidi, Mehdi</creator><creatorcontrib>Holt, Gregory E. ; Batra, Mayank ; Murthi, Mukunthan ; Kambali, Shweta ; Santos, Kayo ; Bastidas, Maria Virginia Perez ; Asif, Huda ; Haddadi, Sara ; Arias, Sixto ; Mirsaeidi, Mehdi</creatorcontrib><description>Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-74328-x</identifier><identifier>PMID: 33051534</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/409 ; 692/699 ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - immunology ; Antibodies, Monoclonal, Humanized - therapeutic use ; Betacoronavirus - isolation & purification ; Coronavirus Infections - drug therapy ; Coronavirus Infections - mortality ; Coronavirus Infections - virology ; COVID-19 ; Female ; Ferritins - analysis ; Humanities and Social Sciences ; Humans ; Interleukin-6 - analysis ; Male ; Middle Aged ; multidisciplinary ; Odds Ratio ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - mortality ; Pneumonia, Viral - virology ; Proportional Hazards Models ; Receptors, Interleukin-6 - immunology ; SARS-CoV-2 ; Science ; Science (multidisciplinary) ; Survival Rate</subject><ispartof>Scientific reports, 2020-10, Vol.10 (1), p.17100-17100, Article 17100</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-10d42f7d0a6997f74349aa8a70e918657500a219d08b5695b85557a316064e143</citedby><cites>FETCH-LOGICAL-c446t-10d42f7d0a6997f74349aa8a70e918657500a219d08b5695b85557a316064e143</cites><orcidid>0000-0001-5298-8442 ; 0000-0003-2880-5217 ; 0000-0002-9420-8691</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555891/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555891/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33051534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holt, Gregory E.</creatorcontrib><creatorcontrib>Batra, Mayank</creatorcontrib><creatorcontrib>Murthi, Mukunthan</creatorcontrib><creatorcontrib>Kambali, Shweta</creatorcontrib><creatorcontrib>Santos, Kayo</creatorcontrib><creatorcontrib>Bastidas, Maria Virginia Perez</creatorcontrib><creatorcontrib>Asif, Huda</creatorcontrib><creatorcontrib>Haddadi, Sara</creatorcontrib><creatorcontrib>Arias, Sixto</creatorcontrib><creatorcontrib>Mirsaeidi, Mehdi</creatorcontrib><title>Lack of tocilizumab effect on mortality in COVID19 patients</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.</description><subject>692/308/409</subject><subject>692/699</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Humanized - immunology</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Betacoronavirus - isolation & purification</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronavirus Infections - virology</subject><subject>COVID-19</subject><subject>Female</subject><subject>Ferritins - analysis</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Interleukin-6 - analysis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Odds Ratio</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - mortality</subject><subject>Pneumonia, Viral - virology</subject><subject>Proportional Hazards Models</subject><subject>Receptors, Interleukin-6 - immunology</subject><subject>SARS-CoV-2</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Survival Rate</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kF1LwzAUhoMobsz9AS-kl95U89kmCILMr8FgN-ptSNt0ZrbNTFrZ_PVGO8e8MTcncN7znMMDwCmCFwgSfukpYoLHEMM4pQTzeH0AhhhSFmOC8eHefwDG3i9heAwLisQxGBACGWKEDsHVTOVvkS2j1uamMp9drbJIl6XO28g2UW1dqyrTbiLTRJP5y_QWiWilWqOb1p-Ao1JVXo-3dQSe7--eJo_xbP4wndzM4pzSpI0RLCgu0wKqRIi0DNdSoRRXKdQC8YSlDEKFkSggz1giWMYZY6kiKIEJ1YiSEbjuuasuq3WRh91OVXLlTK3cRlpl5N9OY17lwn7INIC4QAFwvgU4-95p38ra-FxXlWq07bzElCFEGE1wiOI-mjvrvdPlbg2C8lu87MXLIF7-iJfrMHS2f-Bu5FdzCJA-4EOrWWgnl7ZzTZD2H_YLSpiMxQ</recordid><startdate>20201013</startdate><enddate>20201013</enddate><creator>Holt, Gregory E.</creator><creator>Batra, Mayank</creator><creator>Murthi, Mukunthan</creator><creator>Kambali, Shweta</creator><creator>Santos, Kayo</creator><creator>Bastidas, Maria Virginia Perez</creator><creator>Asif, Huda</creator><creator>Haddadi, Sara</creator><creator>Arias, Sixto</creator><creator>Mirsaeidi, Mehdi</creator><general>Nature Publishing Group UK</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5298-8442</orcidid><orcidid>https://orcid.org/0000-0003-2880-5217</orcidid><orcidid>https://orcid.org/0000-0002-9420-8691</orcidid></search><sort><creationdate>20201013</creationdate><title>Lack of tocilizumab effect on mortality in COVID19 patients</title><author>Holt, Gregory E. ; Batra, Mayank ; Murthi, Mukunthan ; Kambali, Shweta ; Santos, Kayo ; Bastidas, Maria Virginia Perez ; Asif, Huda ; Haddadi, Sara ; Arias, Sixto ; Mirsaeidi, Mehdi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-10d42f7d0a6997f74349aa8a70e918657500a219d08b5695b85557a316064e143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/308/409</topic><topic>692/699</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Humanized - immunology</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Betacoronavirus - isolation & purification</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronavirus Infections - virology</topic><topic>COVID-19</topic><topic>Female</topic><topic>Ferritins - analysis</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Interleukin-6 - analysis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Odds Ratio</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - mortality</topic><topic>Pneumonia, Viral - virology</topic><topic>Proportional Hazards Models</topic><topic>Receptors, Interleukin-6 - immunology</topic><topic>SARS-CoV-2</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holt, Gregory E.</creatorcontrib><creatorcontrib>Batra, Mayank</creatorcontrib><creatorcontrib>Murthi, Mukunthan</creatorcontrib><creatorcontrib>Kambali, Shweta</creatorcontrib><creatorcontrib>Santos, Kayo</creatorcontrib><creatorcontrib>Bastidas, Maria Virginia Perez</creatorcontrib><creatorcontrib>Asif, Huda</creatorcontrib><creatorcontrib>Haddadi, Sara</creatorcontrib><creatorcontrib>Arias, Sixto</creatorcontrib><creatorcontrib>Mirsaeidi, Mehdi</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holt, Gregory E.</au><au>Batra, Mayank</au><au>Murthi, Mukunthan</au><au>Kambali, Shweta</au><au>Santos, Kayo</au><au>Bastidas, Maria Virginia Perez</au><au>Asif, Huda</au><au>Haddadi, Sara</au><au>Arias, Sixto</au><au>Mirsaeidi, Mehdi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of tocilizumab effect on mortality in COVID19 patients</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-10-13</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>17100</spage><epage>17100</epage><pages>17100-17100</pages><artnum>17100</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33051534</pmid><doi>10.1038/s41598-020-74328-x</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5298-8442</orcidid><orcidid>https://orcid.org/0000-0003-2880-5217</orcidid><orcidid>https://orcid.org/0000-0002-9420-8691</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2020-10, Vol.10 (1), p.17100-17100, Article 17100 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7555891 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; PubMed Central; Free Full-Text Journals in Chemistry; EZB Electronic Journals Library |
| subjects | 692/308/409 692/699 Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Betacoronavirus - isolation & purification Coronavirus Infections - drug therapy Coronavirus Infections - mortality Coronavirus Infections - virology COVID-19 Female Ferritins - analysis Humanities and Social Sciences Humans Interleukin-6 - analysis Male Middle Aged multidisciplinary Odds Ratio Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - mortality Pneumonia, Viral - virology Proportional Hazards Models Receptors, Interleukin-6 - immunology SARS-CoV-2 Science Science (multidisciplinary) Survival Rate |
| title | Lack of tocilizumab effect on mortality in COVID19 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A24%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20tocilizumab%20effect%20on%20mortality%20in%20COVID19%20patients&rft.jtitle=Scientific%20reports&rft.au=Holt,%20Gregory%20E.&rft.date=2020-10-13&rft.volume=10&rft.issue=1&rft.spage=17100&rft.epage=17100&rft.pages=17100-17100&rft.artnum=17100&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-74328-x&rft_dat=%3Cproquest_pubme%3E2451135462%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451135462&rft_id=info:pmid/33051534&rfr_iscdi=true |